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 Multitarget drugs: an epigenetic epiphany 
A. Ganesan*[a] 
Abstract: Epigenetics refers to changes in a biological phenotype 
that are not due to an underlying change in genotype. In eukaryotes, 
epigenetics involves a set of chemical modifications of the DNA and 
the histone proteins in nucleosomes. These dynamic changes are 
carried out by enzymes and modulate protein-protein and protein-
nucleic acid interactions to determine whether specific genes are 
expressed or silenced. Both the epigenetic enzymes and recognition 
domains are currently important drug discovery targets, particularly 
for the treatment of cancer. This review summarizes the progress of 
epigenetic targets that have reached a clinical stage i.e. DNA 
methyltransferases, histone deacetylases, lysine methyltransferases, 
lysine demethylases and bromodomains, followed by a 
comprehensive survey of multitarget drugs that have included an 
epigenetic target as one of their mechanisms of action. 
Introduction 
Genetics is broadly defined as the study of genes and their 
heredity. At the molecular level, genetics involves the organism’s 
DNA sequence or genome and how it influences the biological 
phenotype. Genetics has a profound influence on medicinal 
chemistry as mutations in single or multiple genes are directly 
linked to or affect the susceptibility to thousands of human 
diseases. The newer science of epigenetics is concerned not 
with the actual genes but how their expression is regulated.1 In 
eukaryotic organisms, this involves an elaborate pattern of 
structural modification of the DNA and histone proteins that 
constitute the nucleosome. These alterations are introduced by 
a set of enzymes (called ‘writers’) and then serve as recognition 
elements for specific protein-protein and protein-nucleic acid 
interaction domains (the ‘readers’). Meanwhile, a separate set of 
enzymes (the ‘erasers’) reverses the action of the writers. 
Together, the three families of epigenetic players serve to 
coordinate the complex transcription machinery in eukaryotes 
and determine if a specific gene is expressed or silenced. Since 
dysfunctional gene regulation lies at the heart of most human 
ailments, the modulation of epigenetic processes holds much 
promise as a new strategy for drug discovery.2 Over the last two 
decades, small molecules with high affinity and selectivity for 
epigenetic writers, readers and erasers have been identified. 
These efforts have culminated in numerous clinical candidates 
and seven approved anticancer agents (Table 1). 
 
Table 1. Approved epigenetic drugs and examples of compounds in clinical 
development.  The marketer or developer is given in brackets. Abbreviations:  
BRD: bromodomain; DNMT: DNA methyltransferase; HDAC: histone 
deacetylase; KDM: lysine demethylase; KMT: lysine methyltransferase. 
Compound Target Indication Status 
azacitidine 
(Celgene) 
DNMT myelodysplastic 
syndrome 
approved 
FDA, 2004 
decitabine 
(Eisai) 
DNMT myelodysplastic 
syndrome 
approved 
FDA, 2006 
 
vorinostat 
(Merck) 
HDAC cutaneous T-
cell lymphoma 
approved 
FDA, 2006 
romidepsin 
(Celgene) 
HDAC cutaneous T-
cell lymphoma 
approved 
FDA, 2009 
belinostat 
(Spectrum) 
HDAC peripheral T-
cell lymphoma 
approved 
FDA, 2014 
panobinostat 
(Novartis) 
HDAC multiple 
myeloma 
approved 
FDA, 2015 
chidamide 
(Chipscreen) 
HDAC peripheral T-
cell lymphoma 
approved 
CFDA, 2015 
tazemetostat 
(Epizyme) 
KMT leukemia Phase II 
ORY-1001 
(Oryzon) 
KDM leukemia Phase I/II 
GSK525762 
(GlaxoSmithKline) 
BRD NUT midline 
carcinoma 
Phase I/II 
  
Inhibitors of DNA methyltransferases (DNMTs) were the first 
epigenetic drugs to reach the market. DNMTs catalyze the C-6 
methylation of cytosine residues in CpG dinucleotide sequences 
within DNA using the methyl donor S-adenosylmethionine (SAM). 
Cytosine methylation recruits proteins containing methyl binding 
domains (MBD) with an overall gene silencing effect. While 
cytosine methylation is concentrated in non-coding regions in 
normal cells, cancer cells often feature increased methylation at 
promoters of genes encoding for tumor suppressors or other 
proteins with an antiproliferative effect. Hence, DNMT inhibitors 
would reactivate such silenced pathways and have potential 
utility for anticancer therapy.3 
The DNMT catalytic cycle begins with addition of the active site 
cysteine residue to the cytosine base (1, Figure 1) which is 
flipped out of the DNA double helix. This generates an enamine-
like intermediate 2 that is methylated by the SAM cofactor. In the 
final step, 3 undergoes elimination to give the 5-methylcytosine 
product 4 and the regenerated enzyme. In humans, there are 
two key DNMTs, DNMT1 and DNMT3. DNMT1, the most 
abundant, is a ubiquitous enzyme responsible for the 
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 methylation of ‘hemi-methylated’ DNA to maintain the 
methylation status of newly synthesized DNA during rounds of 
replication. DNMT3 is a de novo nethyltransferase that acts 
upon both non-methylated and hemi-methylated DNA. It 
establishes CpG methylation patterns during embryogenesis as 
well as changes to the methylation status in response to the 
environment. Until recently, it was believed that DNA 
demethylation was a passive non-enzymatic process. In 2009, 
the TET (ten-eleven translocation) enzymes were shown to 
sequentially oxidise 5-methylcytosine residues to 5-
hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC) which can then be decarboxylated.4 
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Figure 1. The catalytic cycle of DNA methyltransferases (DNMTs) and the 
mechanism of enzyme inactivation by the inhibitors azacitidine and decitabine. 
The two approved DNMT inhibitors, azacitidine (5) and 
decitabine (6), are prodrugs that contain a 5-azapyrimidine 
heterocycle. Both are metabolically transformed to the active 
species 7 which is incorporated into DNA. The 5-azapyrimidine 
residue is accepted as a DNMT substrate but does not undergo 
the final elimination step due to the lack of a C-5 proton. Instead, 
the enzyme is trapped as the covalent adduct 8 and irreversibly 
inhibited. The two drugs are approved for the treatment of all five 
stages of myelodysplastic syndrome, a hematopoietic stem cell 
disorder that often progresses to acute myeloid leukemia (AML). 
In addition, there are some non-nucleoside DNMT inhibitors at a 
preclinical stage that work by a different mechanism of action by 
competing with the SAM cofactor binding pocket.  
Moving from DNA to histones, the epigenetic post-translational 
modification that has received the most attention is lysine 
acetylation (Figure 2). This is carried out by a large family of 
histone acetyltransferases (HATs) using acetyl CoA as the 
cofactor. Although much effort has been expended on the 
discovery of HAT inhibitors, compounds of high efficacy and 
selectivity suitable for in vivo studies are yet to be disclosed.5 
The complementary HAT erasers are the histone deacetylases 
(HDACs), of which there are eleven human zinc-dependent 
isoforms. These are subdivided according to sequence 
homology and cellular localization into Class I (HDAC1, 2, 3 and 
8), Class IIa (HDAC4, 5, 7, 9), Class IIb (HDAC6 and 10) and 
Class IV (HDAC11).6 Additionally there are seven sirtuins (Class 
III, sirtuins 1-7) implicated in energy homeostasis that hydrolyse 
acetyl-lysine by a different mechanism involving NAD+ as the 
cofactor.7 While HDAC inhibitors are a relatively mature drug 
discovery target with five approvals to date, the inhibition of 
sirtuins is less advanced and at the preclinical stage. 
In histones, lysine acetylation decreases their affinity for DNA 
and opens up the nucleosome permitting gene transcription to 
occur. Furthermore, acetylation is a recruitment signal for 
binding by the bromodomain (see below). By removing histone 
acetylation, HDACs act as gene repressors in a similar fashion 
to DNMTs and the value of HDAC inhibitors lies in the 
reactivation of silenced pathways in cancer cells. Nevertheless, 
it should be kept in mind that the HAT/HDAC nomenclature is 
misleading as reversible lysine acetylation is not restricted to 
histones and occurs in thousands of human proteins. 
Furthermore, many other acylations occur besides acetylation 
such as butyrylation, crotonylation, succinylation and 
biotinylation.8 Part of the therapeutic benefit of inhibiting HDACs, 
or indeed the side effects, may derive from non-epigenetic 
events rather than modulation of the nucleosome. 
All potent inhibitors of the zinc-dependent HDACs have a 
pharmacophore consisting of three elements. First, there is a 
metal-binding warhead that reversibly coordinates to the active 
site zinc cation. Second, there is a spacer that occupies the 
narrow active site channel and mimics the lysine side-chain of 
the substrate. Finally, there is a cap that sits on the enzyme 
surface above the channel and is partially solvent exposed. 
Vorinostat (9, also known as suberoylanilide hydroxamic acid, 
SAHA), the first approved HDAC inhibitor, has a hydroxamic 
acid zinc-binding warhead, a linear spacer and a short phenyl 
cap and is a panHDAC inhibitor. The second approved HDAC 
inhibitor romidepsin (10, also known as FK228), is a natural 
product primarily active against Class I HDACs. It is a prodrug 
containing a disulfide bridge that is reduced in vivo to release 
the thiol zinc-binding warhead in 11. 
The success of vorinostat has spurred many hydroxamic acid 
fast followers that are typically superior in pharmacokinetics 
such as panobinostat (12) as well as benzamides exemplified by 
chidamide (13) which received approval in China in 2014 for the 
treatment of peripheral T-cell lymphoma. Panobinostat is unique 
among the clinical HDAC inhibitors as it is approved for 
refractory or relapsed multiple myeloma rather than the 
treatment of relatively rare T cell lymphomas. It is possible that 
isoform selective HDAC inhibitors will be better tolerated than 
the currently approved drugs and have a broader spectrum of 
applications. One example, rocilinostat (14) is in clinical trials 
and has ten-fold selectivity for HDAC6 over other isoforms. For 
several isoforms, X-ray crystal structures of protein-inhibitor 
 complexes are available and this has facilitated structure-based 
drug design.9  
  
Figure 2. Reversible lysine acetylation and examples of HDAC inhibitors that 
are approved or in clinical development, with zinc-binding warheads in red. 
Three newer epigenetic targets - lysine methyltransferases, 
lysine demethylases and bromodomains - have recently led to 
clinical candidates. Lysine methyltransferases (KMTs) are a 
relatively large family of ~100 enzymes that use SAM as the 
cofactor to methylate lysine residues once, twice or three times 
(Figure 3) while the related arginine methyltransferases 
(PRMTs) perform methylation at arginine residues.10,11 In 
histones, the consequences of methylation are context-
dependent and can lead to either gene activation or repression. 
The drug discovery strategy for KMT inhibition has involved 
reversible occupancy of the SAM cofactor binding pocket. 
Although all KMTs as well as other methyltransferases utilize 
SAM, there are sufficient differences in their binding pocket for 
selective inhibition to be achieved, in much the same way that 
ATP mimetics can be selective for particular kinases. Epizyme’s 
EPZ-5676 (15), the first KMT inhibitor to enter clinical trials, is a 
picomolar inhibitor of DOT1L with greater than 30,000-fold 
selectivity against other KMTs while GlaxoSmithKline’s 
GSK2816126 (16) is a selective EZH2 inhibitor in Phase I trials. 
  
Figure 3. Reversible lysine methylation and two examples of SAM mimetic 
KMT inhibitors in clinical development. 
Lysine demethylases (KDMs) act in opposition to KMTs to erase 
the methyl marks introduced by the latter. They are subdivided 
into two families based on the catalytic mechanism: KDM1 
comprises the lysine-specific demethylases LSD1 and LSD2, 
enzymes that use FAD as a cofactor and are homologous to 
monoamine oxidases (MAOs); KDM2-7, known as the Jumonji 
(JmjC) demethylases, contain about twenty human members 
and are part of the 2-oxoglutarate and iron(II)-dependent 
dioxygenases. The increased expression or activity of both LSD 
and JmjC demethylases is implicated in a variety of cancers. 
Due to the similarity between LSD1 and MAOs, MAO inhibitors 
were investigated for their ability to inhibit LSD1. The old drug 
tranylcypromine (17, Figure 4) is a micromolar LSD1 inhibitor, 
undergoing ring opening to generate a radical intermediate that 
covalently adds to the FAD cofactor. Tranylcypromine analogues 
from Oryzon (18) and GlaxoSmithKline (19) with nanomolar 
potency and high selectivity towards LSD1 over MAOs are 
currently in clinical trials for leukemia while a combination 
therapy of tranylcypromine and all-trans retinoic acid is also 
under investigation. As for the JmjC demethylases, a number of 
preclinical small molecule inhibitors have been reported that act 
by chelation of the active site iron cation.12   
  
Figure 4. The mechanism of action by which tranylcypromine irreversibly 
inhibits MAOs and LSD1 and the structures of LSD1 selective tranylcypromine 
analogues in clinical trials. 
The bromodomains (BRDs) are the first epigenetic readers for 
which ligands have reached clinical validation. These domains, 
of which there are 61 human examples, are approximately 110 
 amino acid residues in size and contain a hydrophobic pocket 
that specifically recognizes acetyl-lysine residues. Among the 
bromodomains, the BET (bromo and extra terminal) domain 
comprising BRD2, BRD3, BRD4 and BRDT has attracted the 
most interest for drug discovery. BRD4 is enriched in enhancer 
regions and drives the expression of oncogenes in cancers while 
translocations fusing BRD3 or BRD4 to the NUT oncogene are 
responsible for NUT midline carcinoma, a cancer with a very 
poor survival rate. Synthetic ligands selective for the BET 
domain include the tool compound JQ1 and examples from 
Resverlogix (20, Figure 5), GlaxoSmithKline (21) and OncoEthix 
(22) undergoing clinical trials.13 
  
Figure 5. Examples of BET ligands in clinical trials.  
Having briefly summarised the major epigenetic targets, we can 
now evaluate their potential in mulitargeted drugs. The 
theoretical basis for such an approach lies in the synergy 
observed between an epigenetic drug and one acting by a 
separate mechanism of action in cell-based and animal models 
for cancer and other indications. Some of these combinations 
are now being tested in clinical trials to provide proof of concept 
in man. In principle, a multiargeted drug would be an alternative 
to such a drug cocktail with the potential advantages of targeting 
two mechanisms through a single agent rather than co-
administration of two drugs. Among the epigenetic targets, 
designing a molecule with such a dual mechanism of action 
would be most challenging with the DNMT inhibitors 5 and 6 due 
to the requirement for a nucleoside with limited scope for further 
elaboration. At the other extreme, the simple pharmacophore of 
HDACs is tolerant of a large variety of cap groups. As this region 
interacts with the enzyme surface, it can be engineered to 
include a second pharmacophore without drastic loss of HDAC 
affinity. Many successful examples have been reported including 
two candidates from Curis in clinical development (see below). 
The other epigenetic targets lie somewhere in between DNMTs 
and HDACs in terms of degree of difficulty of scaffold 
modification to provide multitarget compounds. Earlier examples 
of such multitarget drugs are covered in a review by de Lera.14  
Dual HDAC and kinase inhibitors 
The dual inhibition of protein kinases and HDACs has become 
the most popular choice for epigenetic multitarget drugs which is 
not surprising given the current importance placed on kinases in 
drug discovery.15 In the first publication to demonstrate this 
strategy, Mahboobi et al. designed a set of compounds that 
combine the features of HDAC inhibitors and the approved ABL 
kinase inhibitor imatinib (23, Figure 6).16 Cell-based studies had 
already demonstrated additive effects when these agents were 
administered together, lending support to the multitarget strategy. 
The hybrid compounds contained hydroxamic acids or 
benzamides as HDAC zinc-binding warheads attached through 
linkers to the imatinib scaffold. Examples 24 and 25 illustrate 
how variation of the zinc-binding warhead can affect HDAC 
isoform selectivity. Both compounds were micromolar inhibitors 
of the ABL, PDGFR- and VEGF-R2 kinases and 
antiproliferative at a micromolar level against HeLa and K562 
cell lines. Interestingly, they were equipotent against both wild-
type ABL and the T315I mutant that is resistant to imatinib. 
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Figure 6. The structures of imatinib and analogues that are dual HDAC and 
kinase inhibitors. In this and subsequent figures, IC50 values where available in 
biochemical assays for the drug targets are shown. 
The approved kinase inhibitor erlotinib (26, Figure 7) has served 
as the inspiration for dual HDAC inhibitors that target EGFR, 
HER2 and PDGFR. The X-ray cocrystal structure of erlotinib with 
EGFR indicates that the phenoxy substituents extend beyond 
the ATP binding pocket and should be amenable to 
homologation while retaining affinity. At Curis, erlotinib hybrids 
containing a zinc-binding hydroxamic acid and a spacer linked to 
the quinazoline scaffold were investigated. Variations in chain 
length and substitutions of the quinazoline and phenyl ring were 
examined and numerous analogues were found to be nanomolar 
inhibitors of HDACs, EGFR and HER2.17 From this series, 
CUDC-101 (27) emerged as the clinical candidate. A Phase I 
trial in twelve patients with intermediate or high risk head and 
neck squamous cell carcinoma was recently completed with 
promising results.18 Patients were treated with an intravenous 
dose of 275 mg/m2 of CUDC-101 three times weekly with 
concurrent cisplatin and radiotherapy over seven weeks. 
Pharmacodynamic analysis provided evidence of inhibition of 
both HDACs and EGFR in vivo. At 1.5 years of median follow-up, 
nine patients were free of disease progression, one had a 
recurrence and two had died (neither attributed to the drug). Five 
patients discontinued the drug due to an adverse event 
suggesting that the dosing schedule needs to be improved 
before a larger trial carried out. 
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Figure 7. The approved EGFR inhibitor erlotinib and the dual inhibitor clinical 
candidate CUDC-101. Note: In this and subsequent figures, HDAC refers to an 
 assay against a crude enzyme extract rather than a single recombinant 
isoform. 
Independently, other groups have published dual inhibitors 
based on erlotinib. In a follow-up on their earlier work based on 
imatinib, Mahboobi et al. investigated both the hydroxamic acid 
and benzamide as zinc-binding motifs appended by rigid linkers 
to the quinazoline.19 The hydroxamic acid series exemplified by 
28 (Figure 8) displayed higher inhibition of HDACs but was a 
modest kinase inhibitor compared to the benzamide 29. The 
differences in HDAC isoform selectivity between the two 
compounds are likely due to the different linkers rather than the 
change in zinc-binding warhead. 
  
Figure 8. Structures of HDAC inhibiting erlotinib analogues. 
In a less successful attempt, Zhang replaced the quinazoline 
scaffold with a substituted benzoic acid (30 and 31, Figure 9) 
but these hydroxamic acids were relatively poor in HDAC 
inhibition.20 Another group grafted the zinc-binding group onto 
the aryl ring of erlotinib rather than the quinazoline moiety (32 
and 33).21 Not surprisingly, this resulted in weaker kinase 
inhibition compared to the above examples. The meta-
substituted linker in 33 was significantly better in HDAC 
inhibition compared to the para-substituted 32 whereas the order 
of inhibition against kinases was reversed. 
  
Figure 9. Dual EGFR and HDAC inhibitors. 
Lapatinib (34, Figure 10), an EGFR/HER2 kinase inhibitor, was 
the starting point for a hybrid series reported by Mahboobi et 
al.22 The hydroxamic acid 35 is a nanomolar inhibitor of both 
HDACs and EGFR/HER2 kinases and a micromolar inhibitor of 
cancer cell lines. Meanwhile, 36 is a selective c-Src kinase 
inhibitor that has modest activity in cell-based assays. 
Synergistic effects were observed with panobinostat (12) and 
based on this finding a multitarget analogue was prepared by 
attaching a hydroxamic acid linker through alkene-azide ‘click 
chemistry’.23 Unlike the majority of dual HDAC inhibitors in this 
review, 37 was profiled against the full set of isoforms and found 
to potently inhibit HDACs 1, 3, 6 and 10 while retaining 
submicromolar activity against the kinase. Compound 37 was 
more active than vorinostat or dasatinib alone in a subset of the 
NCI panel of 60 cell lines and was antiproliferative at 
submicromolar levels. 
Targeting kinases is not limited to inhibition, as for example the 
activation of protein kinase C (PKC) resulting in translocation to 
the cell membrane has therapeutic utility. A compound series 
inspired by the indolacatam natural product scaffold was 
investigated by Kozikowski as a dual PKC activator/HDAC 
inhibitor.24 The example 38 is a nanomolar PKC binder and 
activates the enzyme as evidenced by an enhancement of -
secretase processing of amyloid precursor protein in cells at 
concentrations of 0.1-10 M. Metabolic cleavage of the thioester 
would release a free thiol predicted to be a HDAC inhibitor and 
an increase in histone H4 acetylation was observed at 10 M in 
cells. 
Aside from protein kinases, the dual inhibition of HDACs and 
phosphatidylinositol 3-kinase (PI3K) was investigated at Curis by 
preparing hybrids of pictilisib (39), the first P13K inhibitor to 
enter clinical trials. This led to the candidate CUDC-907 (40), a 
potent nanomolar dual HDAC and pan-P13K inhibitor.25 The 
compound was effective in cell lines and a tumor xenograft 
model and is currently in Phase I clinical trials for lymphoma and 
solid tumors.26  
  
 Figure 10. Dual HDAC inhibitors based on lapatinib, c-Src inhibitor 36, PKC 
activation and pictilisib. 
Dual inhibitors of HDACs and non-kinase 
enzymes 
There are a number of multitarget examples where a HDAC 
inhibitor acts upon a second non-kinase enzyme. In an early 
attempt, inhibition of inosine monophosphate dehydrogenase 
(IMPDH) for the treatment of chronic myelogenous leukemia 
was targeted. Mycophenolic acid (41, Figure 11) is a nanomolar 
IMPDH inhibitor used clinically as an immunosuppressant.27 The 
corresponding hydroxamic acid 42 retains activity against 
IMPDH and is additionally a micromolar HDAC inhibitor whereas 
mycophenolic acid itself is inactive against HDACs.28 Additional 
dual inhibitors were designed from synthetic IMPDH inhibitors 
such as Vertex’s clinical candidate merimepodib (43), leading to 
44 and 45.29 The compounds were antiproliferative at a 
micromolar level against the K562 cell line. 
  
Figure 11. Dual HDAC and IMPDH inhibitors based on mycophenolic acid and 
merimepodib. 
 
The statin inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMGCR) have been used for decades to treat 
elevated cholesterol levels and are among the world’s most 
prescribed drugs.30 Recent evidence suggests that HMGCR 
inhibitors have a beneficial effect in cancer. Fang et al. ring 
opened the lactone in the approved drug lovastatin (46, Figure 
12) with hydroxylamine to obtain the hydroxamic acid 47, a dual 
HMGCR and HDAC inhibitor.31 When administered orally, the 
compound was active in a colitis-associated colorectal cancer 
mouse model. Sildenafil (48) is another blockbuster drug that 
served as the seed for a dual inhibitor.32 As a 
phosphodiesterase 5 (PDE5) inhibitor, sildenafil is primarily used 
for the treatment of erectile dysfunction. It has been shown to 
restore cognitive defects in animal models, an outcome also 
observed with HDAC inhibitors. A Spanish patent describes dual 
inhibitors such as 49 that are brain-penetrant and show efficacy 
in mouse models for Alzheimer’s disease.33  
Dual HDAC and DNA targeting agents 
There are a large number of anticancer drugs that act upon DNA 
either by direct binding or interference with enzymes involved in 
DNA biosynthesis or modification.34 Both these classes of 
compounds have been combined with HDAC inhibition to 
provide dual inhibitors. Cisplatin (50, Figure 13) is an approved 
drug that works by cross-linking of the DNA strands. The 
analogue 51 was shown to unwind DNA by an electrophoretic 
mobility shift assay in addition to being a micromolar HDAC1 
inhibitor which however was approximately 8-fold less active in 
HDAC1 inhibition than the precursor malonic acid uncomplexed 
to Pt.35 Bendamustine (52) is another DNA crosslinking nitrogen 
mustard used in the treatment of leukemia and lymphomas and 
is in the WHO’s List of Essential Medicines. The hydroxamic 
acid analogue 53 is a nanomolar HDAC inhibitor and was 
superior to bendamustine in a BCR-ABL-driven acute 
lymphoblastic leukemia mouse model.36 
  
  
Figure 12. HMGCR and PDE5 dual HDAC inhibitors. 
  
Figure 13. Combining DNA covalent modification and HDAC inhibitors. 
 The DNA topoisomerases (Topo I and Topo II) are an important 
anticancer target. Several topoisomerase inhibitors are in use 
clinically and exert their action by formation of a ternary complex 
with the enzyme and DNA substrate. Oyelere was the first to 
report a dual HDAC/topoismerase inhibitor.37,38 The potent 
natural product daunorubicin (54, Figure 14, an approved Topo 
II inhibitor) and camptothecin (55, a Topo I inhibitor with 
approved semisynthetic derivatives) were the starting materials. 
Daunorubicin was linked with a hydroxamic acid bearing 
aldehyde by reductive alkylation to provide 56 while 
camptothecin was connected to a hydroxamic acid by a triazole 
spacer to give 57. Besides being nanomolar HDAC inhibitors 
and antiproliferative in cancer cell lines, these compounds 
inhibited topoisomerase as assessed by DNA decatenation and 
plasmid relaxation assays respectively for 56 and 57. 
  
Figure 14. Dual HDAC and topoismerase inhibitors. 
 
Other groups have prepared dual topoisomerase/HDAC 
inhibitors based on the natural products podophyllotoxin (58, 
Figure 15), evodiamine (59) and the synthetic compound 60. In 
addition to HDAC inhibition, the podophyllotoxin derivative 61 
inhibited Topo II in a DNA relaxation assay.39 While acridine 60 
is a dual Topo I and II inhibitor, the related hydroxamic acid 62 
only inhibited Topo I in DNA relaxation and cleavable-complex 
formation assays.40 The compound showed efficacy in a 
prostate cancer xenograft model. The idea of combining HDAC 
inhibition with Topo I/II inhibition to give a triple inhibitor was 
realized with the evodiamine analogue 63.41 In addition to HDAC 
inhibition, the compound inhibited both Topo I and II in DNA 
relaxation assays and was antiproliferative at micromolar levels. 
 
  
  
Figure 16. Dual HDAC and topoismerase inhibitors. 
Dual epigenetic and receptor ligands 
Upon ligand activation, members of the nuclear receptor 
superfamily translocate to the nucleus and bind to their 
corresponding DNA response elements.42 Combination studies 
have demonstrated synergistic effects between ligands for these 
receptors and HDAC inhibitors, suggesting the feasibility of dual 
targeting. The natural hormone 1,25-dihydroxyvitamin D3 (64, 
Figure 17, 1,25D) and the synthetic ligand LG190178 (65) bind to 
the nuclear vitamin D receptor (VDR) and were the template for 
hydroxamic acids 66 and 67 respectively.43,44,45 In cell-based 
assays, the hydroxamic acids exhibited effects due to combined 
VDR binding and HDAC inhibition. 
  
Figure 17. HDAC inhibitors with dual VDR agonist activity. 
Bexarotene (68, Figure 18) and raloxifene (69) are approved 
 anticancer drugs that bind to the retinoid X (RXR) and estrogen 
receptors (ER) respectively. Bexarotene is an interesting choice 
for combination with a HDAC inhibitor since both drugs are 
clinically used for the treatment of cutaneous T-cell lymphoma. 
The hydroxamic acid derivative 70 displayed dual targeting effects 
in cell-based assays.46 In the case of raloxifene and other ER 
ligands, their value lies in the treatment of ER(+) breast cancers 
that are hormone-dependent. Reactivation of genes by HDAC 
inhibitors has been proposed to resensitize ER(-) hormone-
independent cancers to ER ligands. Among a  library of raloxifene 
hydroxamic acid analogues, one compound 71 was active against 
ER(-) cell lines confirming a dual mechanism of action.47 
  
Figure 18. Dual HDAC inhibitors based on RXR and ER ligands. 
Many natural products comprising diverse chemical structures 
disrupt the microutubule network by either promoting or inhibiting 
the polymerization of tubulin. Some of these have led to important 
anticancer drugs including paclitaxel and vinblastine.48 Colchicine 
(72, Figure 19) contains an amide that can be varied without loss 
of its polymerization inhibiting activity. Taking advantage of this 
SAR, dual inhibitors 73 and 74 were prepared that contain a 
hydroxamic acid and benzamide sidechain respectively.49,50 The 
analogues enforced G2/M cell cycle consistent with microtubule 
disruption in addition to being micromolar HDAC inhibitors. In 74, 
addition of the thiophene moiety to the benzamide conferred 
selectivity towards HDAC2. The same group also reported a 
series derived from the 4-deoxy analogue of podophyllotoxin (58), 
an inhibitor of tubulin polymerization. The HDAC inhibitory activity 
of benzamide 75 was modest against the three isoforms tested.51 
 
  
Figure 19. Dual HDAC and tubulin polymerization inhibitors. 
The RAS small GTPase is part of the ERK signaling cascade and 
approximately a third of human tumors contain mutant forms of 
RAS that are constitutively active.52 RAS is localized at the 
membrane by prenylation at the C-terminus. The farnesylated 
thiosalicylic acid salirasib (76, Figure 20) competes with both 
farnesyl and geranylgeranyl RAS isoforms to inhibit their 
membrane localization as well as formation of the mTOR-raptor 
complex. As the drug acts in synergy with HDAC inhibitors, it is a 
candidate for multitargeting. The hydroxamic acid 77 is a 
submicromolar HDAC inhibitor and interferes with RAS signaling 
as demonstrated by decreased cellular levels of phospho-Akt and 
phospho-ERK1/2, and was more potent than salirasib in growth 
inhibition of cancer cell lines.53 Like ERK, Wnt/β-catenin signaling 
is another pathway that is often aberrantly activated in human 
cancers.54  The seven-transmembrane protein smoothened 
(SMO) is one of the components in this pathway and the SMO 
antagonist vismodegib (78) has recently received approval for the 
treatment of basal cell carcinoma and is synergistic with HDAC 
inhibitors. The hydroxamic acid analogue 79 inhibited both HDAC 
isoforms and SMO-mediated signaling at a nanomolar level.55 In 
support of a dual mechanism of action, 79 retained activity 
against cells with a mutant form of SMO and downregulated the 
expression of Gli-2, effects which are not observed with 
vismodegib on its own. 
In a different approach, rather than modifying a receptor ligand, 
the benzamide clinical candidate HDAC inhibitor entinostat was 
conjugated with a nitric oxide (NO) donor to give 80.56 The hybrid 
compound inhibits HDACs at a micromolar level as well as 
releasing NO leading to the activation of soluble guanylyl cyclase.  
 
   
 
Figure 20. HDAC inhibitors that disrupt ERK, Wnt/β-catenin and NO signaling. 
 
The drug thalidomide (81, Figure 21) was originally used as a 
sedative before being banned due to the teratogenic side effects 
of one enantiomer. Subsequently, there has been renewed 
interest in the drug’s immunomodulatory properties and the 
analogues lenalidomide and pomalidomide are approved for the 
treatment of multiple myeloma. Recently, the molecular target of 
thalidomide was identified as cereblon, a component of the cullin-
dependent ubiquitin ligase that targets bound protein partners for 
degradation by the proteasome.57 Both Bradner and Crews have 
designed multitarget drugs that link the bromodomain ligand JQ1 
to the thalidomide scaffold.  Bradner’s compound 82 resulted in a 
selective and increased degradation of BRD2, BRD3 and BRD4 
and induced apoptosis more rapidly and potently than JQ1 in 
leukemia cell lines.58 At 50 mg/kg, the compound showed 
significant activity in reducing tumor progression in a murine 
leukemia xenograft model. Crews’s ligand 83 featured a longer 
connector between JQ1 and the thalidomide and was a 
nanomolar ligand for BD1 and BD2, the two bromodomains in 
BRD4.59 Compound 83 inhibited B cell proliferation at a higher 
level than JQ1 or pomalidomide alone. 
 
 
 
Figure 21. Bromodomain ligand-thalidomide hybrids that target the 
bromodomain for cereblon-mediated degradation. 
 
Dual epigenetic targeting 
There are several examples where two epigenetic targets have 
been addressed by a single molecule. Investigation of a set of 
dienones with similarities to the natural product curcumin (84, 
Figure 22), a promiscuous hit in various biological assays,60 led 
to compounds such as 85. Although IC50 values were not 
determined, micromolar activity was observed against p300/CBP 
(a histone acetyltransferase), SET7 (a lysine methyltransferase) 
and the SIRT1 and SIRT2 lysine deacetylases.61 The dimeric 
marine natural product psammaplin A (86) is reported to inhibit 
both DNMTs and HDACs.62 An SAR study identified the indole 
analogue 87 as a dual inhibitor of both targets as well as 
sirtuins.63 Meanwhile, the DNMT inhibitory activity of the natural 
product has been called into question by another group.64 
  
Figure 22. Natural product inspired dual epigenetic inhibitors. 
By appending a metal-binding moiety to the KDM1 inhibitor 
tranylcypromine (17), a pan-histone demethylase inhibitor 88 
(Figure 23) that acts upon lysine-specific demethylase as well as 
a set of Jumonji C demethylases at a micromolar level was 
realized.65 The compound induced apoptosis in LNCaP prostate 
cancer and HCT116 colon cancer cell lines and increased 
methylation at histone residues H3K4 and H3K9 was observed. 
GlaxoSmithKline have reported the modification of 
tetrahydroquinoline bromodomain ligands to give rise to the 
hydroxamic acid 89. Although the compound displayed 
antiproliferative effects, no synergy was observed over cellular 
treatment with the combination of a bromodomain ligand and a 
HDAC inhibitor.66 
 
 
Figure 23. Dual demethylase and bromodomain targeting compounds. 
Off-target or dual target 
In the previous sections, we have examined examples whereby a 
multitarget drug has deliberately been engineered. In addition, 
there are instances where an off-target effect has been 
discovered for a drug with an established mechanism of action. 
The first approved HDAC inhibitor vorinostat (9, Figure 24) 
contains a hydroxamic acid warhead which is responsible for its 
activity. It might be expected that the hydroxamic acid would have 
additional activity against other targets through metal binding. The 
JmjC family of lysine demethylases contain an active site iron 
cation and vorinostat was found to inhibit the demethylase 
JMJD2E at a micromolar level.67 Although this is unlikely to be 
physiologically relevant, vorinostat was more active than N-oxalyl 
glycine (90), a standard inhibitor of 2-oxoglutarate and iron(II)-
dependent dioxygenases. The second approved HDAC inhibitor 
romidepsin (10) was also recently identified to have an 
unexpected off-target effect, inhibiting PI3K with an IC50 of 
approximately 50 M.68 By screening a set of synthetic analogues 
of the natural product, the lead 91 was discovered with an 
improved IC50 of 6.7 M.69 
A set of 628 kinase inhibitors was screened for competition 
against an acetylated histone H4 peptide in binding to the BRD4 
bromodomain.70 Interestingly, nine of the compounds displayed 
>90% inhibition at a concentration of 50 M. Volasertib (92), an 
inhibitor of the Polo-like kinase in Phase III clinical trials,71 bound 
to the BRD4 bromodomain in an isothermal titration calorimetry 
assay. In cells, the drug affected biomarkers associated with 
BRD4 at a concentration of 300 nM. As BRD4 has been 
implicated as contributing towards acute myeloid leukemia (AML), 
its antagonism by volasertib may contribute to therapeutic benefit 
in addition to the drug’s primary function of kinase inhibition. The 
study also identified fedratinib (93), a JAK2 inhibitor that reached 
Phase III trials before being discontinued, as a dual BRD4 ligand. 
  
Figure 24. Examples of dual targets discovered with clinical candidates and 
approved drugs. 
Epigenetic multitarget drugs: progress and 
prospects 
In 2007, Pankiewic reported mycophenolic acid derivative 42, the 
 first dual inhibitor aimed at an epigenetic target.  Since then, there 
has been a steady stream of over five examples annually in 
recent years (Figure 25). With two exceptions, 81-82 that target 
the bromodomain and cereblon and 87 which is a dual LSD1 and 
JmjC demethylase inhibitor, all the others include HDAC inhibition 
as one of their mechanisms of action. This is a testament to the 
high flexibility offered by the HDAC pharmacophore as long as the 
zinc-binding warhead and the spacer are retained. Furthermore, 
the biology of HDACs and strategies for their inhibition are better 
understood than that of newer epigenetic targets. To date, HDAC 
inhibition has been combined with the following targets: ABL, 
EGFR, HER2, JAK, PDGFR, P13K, PLK, Src and VEGFR 
kinases; inosine monophosphate dehydrogenase; HMG-CoA 
reductase; phosphodiesterase type 5; DNA crosslinking; DNA 
alkylation; topoisomerase; vitamin D receptor; retinoid X receptor; 
estrogen receptor; tubulin; RAS localization; smoothened and 
guanylyl cyclase. It has also been possible to address two 
epigenetic targets simultaneously by dual inhibition of HDACs and 
DNA methyltransferases, sirtuins, Jumonji C demethylases and 
bromodomains. While this is an impressive list, it is undoubtedly 
growing and future publications will provide further examples. 
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Figure 25. Publication year of multitarget epigenetic drugs cited. 
The challenges for the future in this area remain the same as for 
all multitarget drugs. Firstly, the compounds need to be 
synthetically tractable. In some examples, this was accomplished 
in a concise manner by taking an existing molecule containing a 
carboxylic acid and converting it into a zinc-binding hydroxamic 
acid. However, in the majority of cases, more complex multistep 
routes were needed. Secondly, the resulting compound must 
possess high affinity for both of the intended targets. This is a 
major hurdle that is not easy to meet even with the seemingly 
permissive pharmacophore of the HDAC inhibitors. In this review, 
only a select handful of the compounds inhibit both their intended 
targets with IC50 values ≤100 nM: 27, 29, 35, 40, 47, 49, 79 and 
92. Furthermore, this level of activity needs to be achieved 
without sacrificing physicochemical guidelines for drug-like matter 
that compromise cellular or in vivo applications. Then there is the 
question of which targets will have the biggest impact when 
combined with an epigenetic mechanism of action in a dual 
inhibitor. Thus far, this has been guided by observed synergy 
using drug combinations. Nevertheless, once the desired 
compound has been synthesized, there must be robust evidence 
from biochemical assays as well as cell-based biomarkers that 
both targets are engaged at a meaningful concentration. This 
comes back to the need for high potency, as otherwise the 
compound may predominantly act against one target with a 
modest effect against the other that may be insignificant 
compared to serendipitious improvements in pharmacokinetics. 
Despite these fundamental issues, a tremendous amount of 
progress has been made by academia as well as industry in the 
last decade. A number of epigenetic multitarget drugs are active 
in animal models and two dual HDAC/kinase inhibitors 27 and 40 
from Curis have already advanced to clinical trials. The future 
looks bright for dual inhibitors with an epigenetic flavor and more 
success stories can be anticipated with confidence. 
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